Globus Medical Reports Second Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Globus Medical (GMED) PT Raised to $65 at Needham & Company
August 2, 2018 8:15 AM EDTNeedham & Company raised its price target on Globus Medical (NYSE: GMED) to $65.00 (from $58.00) while maintaining a Buy rating following 2Q earnings report. Revenue was $173M vs. consensus of $168M and non-GAAP EPS was $0.44 vs. consensus of $0.35.
For 2018, GMED raised its revenue... More
